XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2020
Schedule of ownership percentages of investee
    Ownership percentage      
    September 30,     December 31,     Accounting
Name of related party   2020     2019     treatments
Braingenesis Biotechnology Co., Ltd.     0.17 %     0.17 %   Cost Method
Genepharm Biotech Corporation     0.72 %     0.72 %   Cost Method
BioHopeKing Corporation     5.98 %     7.13 %   Cost Method
BioFirst Corporation     15.89 %     15.89 %   Equity Method
Rgene Corporation     31.61 %     31.61 %   Equity Method
Schedule of extent the investee relies

Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment

   September 30,
2020		   December 31,
2019		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,610   $7,367 
Genepharm Biotech Corporation   23,234    22,493 
BioHopeKing Corporation   876,648    1,998,310 
Sub total   907,492    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   284,578    1,336,449 
Rgene Corporation   -    - 
Total  $1,192,070   $3,364,619 
Schedule of equity investments

   Nine Months Ended
September 30,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(1,067,298)  $(182,113)
BioFirst [Member]  
Schedule of balance sheets

   September 30,
 2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $2,401,916   $1,350,701 
Noncurrent Assets   2,435,255    7,450,032 
Current Liabilities   2,594,396    2,060,460 
Noncurrent Liabilities   86,415    78,888 
Shareholders' Equity   2,156,360    6,661,385 
Schedule of statements of operation

   Nine Months Ended
September 30,		 
   2020   2019 
   (Unaudited) 
Net sales  $134,759   $32,235 
Gross profit   6,397    5,048 
Net loss   (4,936,294)   (842,838)
Share of losses from investments accounted for using the equity method   (1,067,298)   (182,113)
Rgene [Member]  
Schedule of balance sheets

   September 30,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $83,651   $82,254 
Noncurrent Assets   403,105    62,768 
Current Liabilities   1,052,028    312,950 
Noncurrent Liabilities   103,497    - 
Shareholders' Deficit   (668,769)   (167,928)
Schedule of statements of operation

   Nine Months Ended
September 30,		 
   2020   2019 
   (Unaudited) 
Net sales  $16,449   $- 
Gross Profit   (332,763)   - 
Net loss   (441,678)   (59,717)
Share of loss from investments accounted for using the equity method   -    -